Cargando…

Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer

Immunotherapy is currently the most promising clinical treatment for lung cancer, not only revolutionizing second-line therapy but now also approved for first-line treatment. However, its clinical efficiency is not high and not all patients benefit from it. Thus, finding the best combination strateg...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Linlin, Du, Changqi, Jiang, Bing, Chen, Lin, Wang, Zibing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600379/
https://www.ncbi.nlm.nih.gov/pubmed/37901223
http://dx.doi.org/10.3389/fimmu.2023.1256740
_version_ 1785125978618462208
author Wang, Linlin
Du, Changqi
Jiang, Bing
Chen, Lin
Wang, Zibing
author_facet Wang, Linlin
Du, Changqi
Jiang, Bing
Chen, Lin
Wang, Zibing
author_sort Wang, Linlin
collection PubMed
description Immunotherapy is currently the most promising clinical treatment for lung cancer, not only revolutionizing second-line therapy but now also approved for first-line treatment. However, its clinical efficiency is not high and not all patients benefit from it. Thus, finding the best combination strategy to expand anti-PD-1/PD-L1-based immunotherapy is now a hot research topic. The conventional use of chemotherapeutic drugs and targeted drugs inevitably leads to resistance, toxic side effects and other problems. Recent research, however, suggests that by adjusting the dosage of drugs and blocking the activation of mutational mechanisms that depend on acquired resistance, it is possible to reduce toxic side effects, activate immune cells, and reshape the immune microenvironment of lung cancer. Here, we discuss the effects of different chemotherapeutic drugs and targeted drugs on the immune microenvironment. We explore the effects of adjusting the dosing sequence and timing, and the mechanisms of such responses, and show how the effectiveness and reliability of combined immunotherapy provide improved treatment outcomes.
format Online
Article
Text
id pubmed-10600379
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106003792023-10-27 Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer Wang, Linlin Du, Changqi Jiang, Bing Chen, Lin Wang, Zibing Front Immunol Immunology Immunotherapy is currently the most promising clinical treatment for lung cancer, not only revolutionizing second-line therapy but now also approved for first-line treatment. However, its clinical efficiency is not high and not all patients benefit from it. Thus, finding the best combination strategy to expand anti-PD-1/PD-L1-based immunotherapy is now a hot research topic. The conventional use of chemotherapeutic drugs and targeted drugs inevitably leads to resistance, toxic side effects and other problems. Recent research, however, suggests that by adjusting the dosage of drugs and blocking the activation of mutational mechanisms that depend on acquired resistance, it is possible to reduce toxic side effects, activate immune cells, and reshape the immune microenvironment of lung cancer. Here, we discuss the effects of different chemotherapeutic drugs and targeted drugs on the immune microenvironment. We explore the effects of adjusting the dosing sequence and timing, and the mechanisms of such responses, and show how the effectiveness and reliability of combined immunotherapy provide improved treatment outcomes. Frontiers Media S.A. 2023-10-09 /pmc/articles/PMC10600379/ /pubmed/37901223 http://dx.doi.org/10.3389/fimmu.2023.1256740 Text en Copyright © 2023 Wang, Du, Jiang, Chen and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Linlin
Du, Changqi
Jiang, Bing
Chen, Lin
Wang, Zibing
Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer
title Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer
title_full Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer
title_fullStr Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer
title_full_unstemmed Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer
title_short Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer
title_sort adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600379/
https://www.ncbi.nlm.nih.gov/pubmed/37901223
http://dx.doi.org/10.3389/fimmu.2023.1256740
work_keys_str_mv AT wanglinlin adjustingthedoseoftraditionaldrugscombinedwithimmunotherapyreshapingtheimmunemicroenvironmentinlungcancer
AT duchangqi adjustingthedoseoftraditionaldrugscombinedwithimmunotherapyreshapingtheimmunemicroenvironmentinlungcancer
AT jiangbing adjustingthedoseoftraditionaldrugscombinedwithimmunotherapyreshapingtheimmunemicroenvironmentinlungcancer
AT chenlin adjustingthedoseoftraditionaldrugscombinedwithimmunotherapyreshapingtheimmunemicroenvironmentinlungcancer
AT wangzibing adjustingthedoseoftraditionaldrugscombinedwithimmunotherapyreshapingtheimmunemicroenvironmentinlungcancer